Hyperfine

Hyperfine is a Guilford, Connecticut medical-device company spun out of serial-entrepreneur Jonathan Rothberg in 2014 and listed via SPAC in December 2021. The single product is the Swoop Portable MR Imaging System — a wheeled, point-of-care MRI scanner that uses a 64 milliTesla permanent magnet instead of the 1.5 to 3 Tesla superconducting magnets in conventional MRI suites. The result is a device that plugs into a standard 120-volt wall outlet, weighs roughly 700 kilograms (about a tenth of a fixed scanner) and rolls bedside in the ICU, NICU, emergency department or stroke unit.

The trade-off is image quality: at 64 milliTesla, Swoop cannot match the spatial resolution of a 3-Tesla scanner for elective imaging. The wedge Hyperfine occupies is narrower and harder to attack — bedside neuro imaging where the alternative is no imaging at all, or a 4-hour wait, or an ambulance transfer. FDA 510(k) clearance is in hand for adult and pediatric brain imaging; CE-mark is active in Europe.

Revenue growth in Q1 2026 was 82.6 percent year-over-year, lifting trailing revenue to roughly 15.3 million USD. Gross margin sits at 51.2 percent, which is the genuinely interesting number — for a single-digit-million-revenue medical device, 50 percent gross is the threshold above which scale economics actually exist. Operating margin is still minus 219 percent because the fixed overhead of a public medtech (regulatory, clinical, public-company costs) is amortized over a tiny revenue base. Free cash flow is minus 16.3 million USD trailing — manageable against the roughly 60 million USD cash balance, giving Hyperfine close to 4 years of runway at the current burn.

The shareholder register is unusual. Jonathan Rothberg — founder of Ion Torrent (sold to Life Technologies for 725 million USD in 2010), 4Catalyzer holding company, and a string of medical-device platforms — controls roughly 30 percent of Hyperfine common stock through 4Catalyzer and personal holdings. Rothberg has not sold shares on the open market in any quarter since the de-SPAC; insider buying has appeared in 2025 at sub-1 USD levels.

Institutional ownership is concentrated in healthcare-specialist funds — Camber Capital, Perceptive Advisors and a handful of dedicated medtech vehicles. There is essentially no generalist long ownership at this size and price, which is mechanically the reason Hyperfine trades like a binary option: there is no marginal buyer until the revenue inflection convinces an institutional checklist that the asset is investable. Short interest is moderate at 1.25 percent of float — neither a squeeze setup nor a meaningful bear thesis from the smart-money short universe.

The signal worth tracking is the Rothberg 4Catalyzer pattern: he typically does not sell into commercial inflection. The Hyperfine register is structurally illiquid because the controlling holder is patient.

At 1.55 USD the market cap is 153.9 million USD and trailing revenue is roughly 15.3 million USD — a 10.0x EV/Sales multiple that on its face looks rich for a cash-burning device company. The peer screen is the relevant frame: Butterfly Network trades at roughly 4x EV/Sales on 80 million USD revenue and 30 percent growth; Inspire Medical at 8x on 800 million USD revenue and 50 percent growth; Penumbra at 6x on 1.2 billion USD revenue and 25 percent growth. Hyperfines 10x is justified only if the 82 percent growth holds for two more years. The bridge from 15 million USD to 50 million USD revenue at 50 percent gross margin and minus 15 million USD FCF puts a credible 2028 EV/Sales floor at 4x — implying a 200 million USD market cap at the same share count, or roughly 2.10 USD share price, broadly in line with the 2.25 USD analyst consensus. The asymmetry is the optionality on a strategic-acquirer bid (Siemens, GE, Philips, or a 4Catalyzer roll-up with Butterfly) — where 6-8x forward EV/Sales on 50 million USD is plausible, putting the take-out range at 3-4 USD per share.

1. Q3 2026 (August 2026): Q2 2026 earnings call. The trailing revenue trajectory needs to hold the 70-plus percent growth rate to keep the EV/Sales multiple defensible. Unit install count update (currently around 280-320) and any commentary on the pending CPT-code application are the watch items.
2. Q4 2026 (November 2026): RSNA — the Radiological Society of North America annual meeting in Chicago. Largest imaging-industry conference globally. Historical Swoop-related announcements (new clinical evidence, hospital-system partnerships, AI algorithm releases) cluster around this event.
3. H1 2027: Expected first regulatory filings for body-imaging Swoop variant (currently brain-only). Expansion beyond neuro is the multi-year unlock that takes Hyperfines TAM from 1.2 billion USD (neuro) to 8-plus billion USD (full-body point-of-care imaging).

Hyperfine is the asset where Jonathan Rothbergs track record matters more than any single quarterly print. Rothberg built Ion Torrent into a 725 million USD sale to Life Technologies, founded Butterfly Network (currently 200 million USD market cap on 80 million USD revenue) and has shown the willingness to hold portfolio companies through extended commercialization curves. Hyperfine is in the same pattern — a single-product device with a sharp clinical-workflow wedge, currently too small for any generalist fund, growing at a rate that mechanically rerates the multiple if it continues for 18 more months.

The bull case is not the analyst 2.25 USD target — that is a fair-value print. The asymmetric outcome is a strategic combination with Butterfly Network at a 4Catalyzer-level decision, or an outright Siemens/GE acquisition once point-of-care MRI is proven to scale past 100 million USD annual revenue. Both paths put fair value at 3-4 USD. The bear case is the dilution overhang and the silent CPT-code risk — both are real, both are why this trades at 1.55 USD.

Position sizing for retail: this is a binary-outcome speculation, not a core medtech holding. The 51 percent gross margin and the 82 percent growth rate are real and unusual at this revenue size. Size accordingly.